Kristin Ranheim Randel

Kristin Ranheim Randel

Auto-generated profile, based on publicly available information

Kristin Ranheim Randel

Department of Colorectal Cancer Screening, Cancer Registry of Norway, Norwegian Institute of Public Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Gastroenterology
Verified
Journal Article
Open access
PDF file
KRKristin R. Randel
Kristin R. Randel
ASAnna L. Schult
Anna L. Schult
EBEdoardo Botteri
Edoardo Botteri
GHGeir Hoff
Geir Hoff
MBMichael Bretthauer
Michael Bretthauer
ØHØyvind Holme
Øyvind Holme
Background and aims The comparative effectiveness of sigmoidoscopy and fecal immunochemical testing (FIT) for colorectal cancer (CRC) screening is unknown. Methods Individuals aged 50–74 years living in South-East Norway were randomly invited between 2012 and 2019 to either once-only flexible sigmoidoscopy or FIT screening every second year. Colonoscopy was recommended after sigmoidoscopy if any polyp ≥10 mm, ≥ three adenomas, any advanced adenomas, or CRC was found or subsequent to FIT > 15 μg hemoglobin/g feces. Data for this report were obtained after complete recruitment in both groups and included two full FIT rounds and part of the third round. Outcome measures were participation, neoplasia detection, and adverse events. Age-standardized detection rates and age-adjusted odds ratios (OR) were calculated. Results We included 139,291 individuals; 69,195 randomized to sigmoidoscopy and 70,096 to FIT. Participation rate was 52% for sigmoidoscopy, 58% in the first FIT round and 68% for three cumulative FIT rounds. Compared to sigmoidoscopy, detection rate for CRC was similar in the first FIT round (0.25% vs 0.27%, OR 0.92, 95% CI 0.75-1.13), but higher after three FIT rounds (0.49% vs 0.27%, OR 1.87, 95% CI 1.54-2.27). Advanced adenoma detection rate was lower in the first FIT round compared to sigmoidoscopy, 1.4% vs 2.4% (OR 0.57, 95% CI 0.53-0.62), but higher after three cumulative FIT rounds, 2.7% vs 2.4% (OR 1.14, 95% CI 1.05-1.23). There were 33 (0.05%) serious adverse events in the sigmoidoscopy group compared to 47 (0.07%) in the FIT group (p =.13). Conclusion Participation was higher and more CRC and advanced adenomas were detected with repeated FIT compared to sigmoidoscopy. The risk of perforation and bleeding was comparable. Clinicaltrials.gov (NCT 01538550).

1 May 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
KRKristin Ranheim Randel
Kristin Ranheim Randel
EBEdoardo Botteri
Edoardo Botteri
KRKatrine Maria Kauczynska Romstad
Katrine Maria Kauczynska Romstad
SFSvein Oskar Frigstad
Svein Oskar Frigstad
MBMichael Bretthauer
Michael Bretthauer
ØHØyvind Holme
Øyvind Holme

1 July 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
ASAnna Lisa Schult
Anna Lisa Schult
EBEdoardo Botteri
Edoardo Botteri
GHGeir Hoff
Geir Hoff
KRKristin R Randel
Kristin R Randel
EDEirin Dalén
Eirin Dalén
TLThomas de Lange
Thomas de Lange
Objectives To assess detection rates for colorectal cancer (CRC) and advanced adenomas in asymptomatic CRC screening participants and bowel symptoms in association with CRC and advanced adenoma. Design Cross-sectional study. Setting Two screening centres. Participants 42 554 men and women, aged 50–74 years, participating in a randomised CRC screening trial. 36 059 participants underwent a sigmoidoscopy (and follow-up colonoscopy if positive sigmoidoscopy) and 6495 underwent a colonoscopy after a positive faecal immunochemical test (FIT). Primary and secondary outcome measures Proportion of asymptomatic participants diagnosed with CRC or advanced adenomas. Prevalence of bowel symptoms (rectal bleeding, change in bowel habits, diarrhoea, constipation, bloating, alternating bowel habits, general symptoms, other bowel symptoms) recorded by the endoscopist and their association with CRC and advanced adenomas. Results Among sigmoidoscopy participants, 7336 (20.3%) reported at least one symptom. 120 (60%) out of 200 individuals with screen-detected CRC and 1301 (76.5%) out of 1700 with advanced adenoma were asymptomatic. Rectal bleeding was associated with detection of CRC and advanced adenoma (OR 4.3, 95% CI 3.1 to 6.1 and 1.8, 95% CI 1.5 to 2.1, respectively), while change in bowel habits only with CRC detection (OR 3.8, 95% CI 2.4 to 6.1). Among the FIT positives, 2173 (33.5%) reported at least one symptom. Out of 299 individuals with screen-detected CRC and 1639 with advanced adenoma, 167 (55.9%) and 1 175 (71.7%) were asymptomatic, respectively. Detection of CRC was associated with rectal bleeding (OR 1.8, 95% CI 1.4 to 2.3), change in bowel habits (OR 2.2, 95% CI 1.4 to 3.5) and abdominal pain (OR 1.8, 95% CI 1.2 to 2.7). Conclusions Some bowel symptoms increased the likelihood of being diagnosed with CRC or advanced adenoma. However, the majority of individuals with these findings were asymptomatic. Asymptomatic individuals should be encouraged to participate in CRC screening. Trial registration number Clinicaltrials.gov Identifier: NCT01538550.

1 February 2024 in American Journal of Gastroenterology
Verified
Journal Article
Open access
SNSara Nafisi
Sara Nafisi
NSNathalie C. Støer
Nathalie C. Støer
MVMarit B Veierød
Marit B Veierød
KRKristin R. Randel
Kristin R. Randel
GHGeir Hoff
Geir Hoff
EBEdoardo Botteri
Edoardo Botteri
INTRODUCTION: To examine the association between low-dose aspirin use and risk of colorectal cancer (CRC). METHODS: In this nationwide cohort study, we identified individuals aged 50 years or older residing for 6 months or more in Norway in 2004–2018 and obtained data from national registers on drug prescriptions, cancer occurrence, and sociodemographic factors. Multivariable Cox regression models were used to estimate the association between low-dose aspirin use and CRC risk. In addition, we calculated the number of CRC potentially averted by low-dose aspirin use. RESULTS: We included 2,186,390 individuals. During the median follow-up of 10.9 years, 579,196 (26.5%) used low-dose aspirin, and 38,577 (1.8%) were diagnosed with CRC. Current use of aspirin vs never use was associated with lower CRC risk (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.84–0.90). The association was more pronounced for metastatic CRC (HR 0.79; 95% CI 0.74–0.84) than regionally advanced (HR 0.89; 95% CI 0.85–0.92) and localized CRC (HR 0.93; 95% CI 0.87–1.00; P heterogeneity = 0.001). A significant trend was found between duration of current use and CRC risk: HR 0.91 (95% CI 0.86–0.95) for <3 years, HR 0.85 (0.80–0.91) for ≥3 and <5 years, and HR 0.84 (0.80–0.88) for ≥5 years of use vs never use (P trend < 0.001). For past use, HR were 0.89 (95% CI 0.84–0.94) for <3 years, 0.90 (0.83–0.99) for ≥3 and <5 years, and 0.98 (0.91–1.06) for ≥5 years since last use vs never use (P-trend < 0.001). We estimated that aspirin use averted 1,073 cases of CRC (95% CI 818–1,338) in the study period. DISCUSSION: In this nationwide cohort, use of low-dose aspirin was associated with a lower risk of CRC.

8 October 2022 in American Journal of Preventive Medicine
Verified
Journal Article
Open access
BKBenedicte Kirkøen
Benedicte Kirkøen
PBPaula Berstad
Paula Berstad
GHGeir Hoff
Geir Hoff
TBTomm Bernklev
Tomm Bernklev
KRKristin R. Randel
Kristin R. Randel
EBEdoardo Botteri
Edoardo Botteri
The effectiveness of colorectal cancer screening programs depends on the participation rate. This study examined the association between type and severity of mental illness and colorectal cancer screening participation. Between 2012 and 2017, a total of 46,919 individuals were invited to sigmoidoscopy screening in Norway, and 70,019 were invited to fecal immunochemical testing. In 2022, logistic regression was used to evaluate the association between the use of antipsychotics, anxiolytics, hypnotics, and antidepressants in the year preceding the screening invitation and screening participation, adjusted for demographic and socioeconomic factors. Defined daily doses of individual drugs were used to assess dose‒response relationships. Overall, 19.2% (24.8% of women, 13.4% of men) of all invitees used at least 1 psychotropic medication. Nonparticipation in the 2 arms combined was associated with the use of anxiolytics (60.7% in users vs 43.2% in nonusers; OR=1.53; 95% CI=1.45, 1.62) and antipsychotics (64.3% vs 43.8%; OR=1.41; 95% CI=1.30, 1.53) and increased with higher doses for both drugs. Hypnotics and antidepressants were only weakly associated with nonparticipation in higher doses. Participation rates were 57.3%, 52.3%, 42.9%, and 35.4% in those prescribed 0, 1, 2, and 3-4 classes of psychotropic medications, respectively. The associations between the use of psychotropic medications and nonparticipation were similar for the 2 screening tests. These findings show significant disparities in colorectal cancer screening participation for individuals with mental illness, independent of the screening method. Moreover, screening participation varied depending on the type and severity of mental illness. Targeted interventions are warranted to ensure that people with mental illness are supported to access the benefits of colorectal cancer screening.

22 April 2022 in International Journal of Cancer
Verified
Journal Article
Open access
EBEdoardo Botteri
Edoardo Botteri
GHGeir Hoff
Geir Hoff
KRKristin R. Randel
Kristin R. Randel
ØHØyvind Holme
Øyvind Holme
TLThomas de Lange
Thomas de Lange
PBPaula Berstad
Paula Berstad
Public health systems should guarantee universal access to health care services, including cancer screening. We assessed whether certain population subgroups were underrepresented among participants in colorectal cancer screening with sigmoidoscopy and faecal immunochemical testing (FIT). Between 2012 and 2019, about 140 000 individuals aged 50 to 74 years were randomly invited to once‐only sigmoidoscopy or first round of FIT screening. Our study included 46 919 individuals invited to sigmoidoscopy and 70 019 to FIT between 2012 and 2017. We used logistic regression models to evaluate if demographic and socioeconomic factors and use of certain drugs were associated with participation. Twenty‐four thousand one hundred and fifty‐nine (51.5%) individuals attended sigmoidoscopy and 40 931 (58.5%) FIT screening. Male gender, young age, low education and income, being retired or unemployed, living alone, being an immigrant, long driving time to screening centre, and use of antidiabetic and psychotropic drugs were associated with low participation in both screening groups. Many of these factors also predicted low acceptance of colonoscopy after positive FIT. While male gender, young age and living alone were more strongly associated with nonparticipation in FIT than sigmoidoscopy, low education and income, being retired or immigrant and long driving time were more strongly associated with nonparticipation in sigmoidoscopy than FIT. In conclusion, participation was lower in sigmoidoscopy than FIT. Predictors of nonparticipation were similar between arms. However, low socioeconomic status, being an immigrant and long driving time affected participation more in sigmoidoscopy screening, suggesting that FIT may guarantee more equal access to screening services than sigmoidoscopy.